Valeo Pharma (VPHIF – Research Report) received a Buy rating and a C$1.00 price target from Echelon Wealth Partners analyst Stefan Quenneville today. The company’s shares closed today at $0.40.
According to TipRanks, Quenneville is an analyst with an average return of -8.7% and a 36.25% success rate. Quenneville covers the Healthcare sector, focusing on stocks such as Antibe Therapeutics, Cognetivity Neurosciences, and Valeo Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Valeo Pharma with a $0.73 average price target.
See today’s best-performing stocks on TipRanks >>
Based on Valeo Pharma’s latest earnings release for the quarter ending July 31, the company reported a quarterly revenue of $6.07 million and a GAAP net loss of $4.74 million. In comparison, last year the company earned a revenue of $5.67 million and had a GAAP net loss of $2.97 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Valeo Pharma Inc a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing or similar arrangements. Its current markets its product Synacthen Depot which is a synthetic ACTH product that is used in conditions where the production of natural cortisol and other hormones is desired.
